918 research outputs found
Meta-analysis of generalized additive models in neuroimaging studies
Contains fulltext :
231772.pdf (publisher's version ) (Open Access)Analyzing data from multiple neuroimaging studies has great potential in terms of increasing statistical power, enabling detection of effects of smaller magnitude than would be possible when analyzing each study separately and also allowing to systematically investigate between-study differences. Restrictions due to privacy or proprietary data as well as more practical concerns can make it hard to share neuroimaging datasets, such that analyzing all data in a common location might be impractical or impossible. Meta-analytic methods provide a way to overcome this issue, by combining aggregated quantities like model parameters or risk ratios. Most meta-analytic tools focus on parametric statistical models, and methods for meta-analyzing semi-parametric models like generalized additive models have not been well developed. Parametric models are often not appropriate in neuroimaging, where for instance age-brain relationships may take forms that are difficult to accurately describe using such models. In this paper we introduce meta-GAM, a method for meta-analysis of generalized additive models which does not require individual participant data, and hence is suitable for increasing statistical power while upholding privacy and other regulatory concerns. We extend previous works by enabling the analysis of multiple model terms as well as multivariate smooth functions. In addition, we show how meta-analytic p-values can be computed for smooth terms. The proposed methods are shown to perform well in simulation experiments, and are demonstrated in a real data analysis on hippocampal volume and self-reported sleep quality data from the Lifebrain consortium. We argue that application of meta-GAM is especially beneficial in lifespan neuroscience and imaging genetics. The methods are implemented in an accompanying R package metagam, which is also demonstrated
Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences.
The locus coeruleus (LC), the origin of noradrenergic modulation of cognitive and behavioral function, may play an important role healthy ageing and in neurodegenerative conditions. We investigated the functional significance of age-related differences in mean normalized LC signal intensity values (LC-CR) in magnetization-transfer (MT) images from the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) cohort - an open-access, population-based dataset. Using structural equation modelling, we tested the pre-registered hypothesis that putatively noradrenergic (NA)-dependent functions would be more strongly associated with LC-CR in older versus younger adults. A unidimensional model (within which LC-CR related to a single factor representing all cognitive and behavioral measures) was a better fit with the data than the a priori two-factor model (within which LC-CR related to separate NA-dependent and NA-independent factors). Our findings support the concept that age-related reduction of LC structural integrity is associated with impaired cognitive and behavioral function
Nanoparticle mediated silencing of DNA repair sensitizes pediatric brain tumor cells to y-irradiation
Medulloblastoma (MB) and ependymoma (EP) are the most common pediatric brain tumors, afflicting 3000 children annually. Radiotherapy (RT) is an integral component in the treatment of these tumors; however, the improvement in survival is often accompanied by radiation-induced adverse developmental and psychosocial sequelae. Therefore, there is an urgent need to develop strategies that can increase the sensitivity of brain tumors cells to RT while sparing adjacent healthy brain tissue. Apurinic endonuclease 1 (Ape1), an enzyme in the base excision repair pathway, has been implicated in radiation resistance in cancer. Pharmacological and specificity limitations inherent to small molecule inhibitors of Ape1 have hindered their clinical development. Here we report on a nanoparticle (NP) based siRNA delivery vehicle for knocking down Ape1 expression and sensitizing pediatric brain tumor cells to RT. The NP comprises a superparamagnetic iron oxide core coated with a biocompatible, biodegradable coating of chitosan, polyethylene glycol (PEG), and polyethyleneimine (PEI) that is able to bind and protect siRNA from degradation and to deliver siRNA to the perinuclear region of target cells. NPs loaded with siRNA against Ape1 (NP:siApe1) knocked down Ape1 expression over 75% in MB and EP cells, and reduced Ape1 activity by 80%. This reduction in Ape1 activity correlated with increased DNA damage post-irradiation, which resulted in decreased cell survival in clonogenic assays. The sensitization was specific to therapies generating abasic lesions as evidenced by NP:siRNA not increasing sensitivity to paclitaxel, a microtubule disrupting agent. Our results indicate NP-mediated delivery of siApe1 is a promising strategy for circumventing pediatric brain tumor resistance to RT
The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs
Contains fulltext :
237767.pdf (Publisherβs version ) (Open Access)Ravulizumab is a very expensive complement C5-inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria, with a fixed-dosing interval of 8 weeks. For lifelong treatment, a cost-effective and patient-friendly dosing strategy is preferred. We therefore explored alternative ravulizumab dosing regimens in silico based on the thorough dose-finding studies of the manufacturer. Extending the interval to 10 weeks or individually extending the interval to a mean of 12.8 weeks based on pharmacokinetic monitoring resulted in noninferior efficacy in terms of lactate dehydrogenase normalization, with drug cost savings up to 37%. We here show the potential of individualized ravulizumab dosing to improve patient-friendliness at reduced costs
Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up.
The aims of our study were to assess the effect of follow-up on the quality of life of colorectal cancer patients and to assess the attitudes of patients towards follow-up as a function of patient characteristics. Patients who had been treated with curative intent were selected from four types of hospitals. Eighty-two patients were interviewed using a structured questionnaire, whereas 130 patients received the questionnaire by mail. To assess the effect of follow-up on the quality of life, the interviewed patients were randomly allocated to three groups and interviewed at different times in relation to the follow-up visit. Analysis did not show an effect of the follow-up visit on quality of life. Patients reported a positive attitude towards follow-up: it reassured them, they judged the communication with the physician to be positive, and they experienced only slight nervous anticipation and few other disadvantages. Patients reported a strong preference for follow-up, and a large majority would prefer follow-up even if it would not lead to earlier detection of a recurrence. Apart from living situation, no patient characteristics were clearly associated with the attitude towards follow-up. Implications for clinical practice are discussed
Π‘Π²ΡΠ·ΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΡΡΠ΅Π΄Π½Π΅ΠΌΠ΅ΡΡΡΠ½ΡΡ ΠΠ‘Π Π½Π°Π΄ ΠΠ½ΡΠ°ΡΠΊΡΠΈΠΊΠΎΠΉ ΠΈ ΠΏΠ»ΠΎΡΠ°Π΄ΠΈ ΡΠ΅ΠΏΠ»ΠΎΠ³ΠΎ ΡΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±Π°ΡΡΠ΅ΠΉΠ½Π° Π’ΠΈΡ ΠΎΠ³ΠΎ ΠΎΠΊΠ΅Π°Π½Π° ΠΏΡΠΈ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΠΏΠΎΡΠ΅ΠΏΠ»Π΅Π½ΠΈΠΈ ΠΊΠ»ΠΈΠΌΠ°ΡΠ°
ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠ±ΡΠ°Π½Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ
ΡΡΠ΅Π΄Π½Π΅ΠΌΠ΅ΡΡΡΠ½ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ ΠΠ‘Π Π½Π°Π΄ ΠΠ½ΡΠ°ΡΠΊΡΠΈΠΊΠΎΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠ»ΠΎΡΠ°Π΄ΠΈ Π’Π’Π Π² Π·Π°ΠΏΠ°Π΄Π½ΠΎΠΌ ΠΏΠΎΠ»ΡΡΠ°ΡΠΈΠΈ. ΠΡΠ΅Π΄ΠΌΠ΅ΡΠΎΠΌ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΅ΡΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ²ΡΠ·Π΅ΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΊΠ°Π·Π°Π½Π½ΡΠΌΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ°ΠΌΠΈ, ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΠ²ΡΠΈΠΌΠΈ
Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠ΅ΠΏΠ»Π΅Π½ΠΈΡ ΠΊΠ»ΠΈΠΌΠ°ΡΠ°. Π¦Π΅Π»ΡΡ ΡΠ°Π±ΠΎΡΡ Π΅ΡΡΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΈΡ
ΡΠ²ΡΠ·Π΅ΠΉ, ΠΊΠΎΡΠΎΡΡΠ΅ Π½Π°
ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠ΅ΠΏΠ»Π΅Π½ΠΈΡ ΠΊΠ»ΠΈΠΌΠ°ΡΠ° ΡΡΠΈΠ»ΠΈΠ²Π°Π»ΠΈΡΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎ ΠΈ Π½ΡΠ½Π΅ ΡΠ²Π»ΡΡΡΡΡ
Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ
- β¦